Cardiac disease evaluation and management among kidney and liver transplantation candidates: A scientific statement from the american heart association and the American college of cardiology foundation

Circulation

Volumn 126, Issue 5, 2012, Pages 617-663

  Lentine, Krista L ^a   Costa, Salvatore P ^a   Weir, Matthew R ^a   Robb, John F ^a   Fleisher, Lee A ^a   Kasiske, Bertram L ^a   Carithers, Robert L ^a   Ragosta, Michael ^a   Bolton, Kline ^a   Auerbach, Andrew D ^a   Eagle, Kim A ^a  

^a NONE

Author keywords

AHA Scientific Statements; coronary disease; exercise test; kidney; liver; preoperative evaluation; transplantation

Indexed keywords

ACETYLSALICYLIC ACID; BIOLOGICAL MARKER; CANDESARTAN; CARVEDILOL; FLUINDOSTATIN; FOSINOPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; ROSUVASTATIN; THIENOPYRIDINE DERIVATIVE;

ALLOGRAFT; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL EVALUATION; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; ECHOCARDIOGRAPHY; EXERCISE TEST; EXERCISE TOLERANCE; HEART DISEASE; HEART TRANSPLANTATION; HUMAN; KIDNEY FAILURE; KIDNEY PANCREAS TRANSPLANTATION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MEDICAL SOCIETY; MYOCARDIAL DISEASE; NON INVASIVE PROCEDURE; PERCUTANEOUS CORONARY INTERVENTION; PERIOPERATIVE PERIOD; PRACTICE GUIDELINE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVASCULARIZATION; RISK ASSESSMENT; STRESS ECHOCARDIOGRAPHY; TREATMENT OUTCOME; VALVULAR HEART DISEASE;

DISEASE MANAGEMENT; HEART DISEASES; HUMANS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; PATIENT SELECTION; PERIOPERATIVE PERIOD; RISK FACTORS;

EID: 84864475111     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIR.0b013e31823eb07a     Document Type: Article

References (303)

1. Health Resources and Services Administration. Organ Procurement and Transplant Network Database. Available at: http://optn.transplant.hrsa. gov/. Accessed September 7, 2011.
2. Lentine KL, Brennan DC, Schnitzler MA. Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol. 2005;16:496-506. (Pubitemid 41725147)
3. Kasiske BL, Maclean JR, Snyder JJ. Acute myocardial infarction and kidney transplantation. J Am Soc Nephrol. 2006;17:900-7.
4. Lentine KL, Schnitzler MA, Abbott KC, et al. De novo congestive heart failure after kidney transplantation: a common condition with poor prognostic implications. Am J Kidney Dis. 2005;46:720-33. (Pubitemid 41383951)
5. Lentine KL, Schnitzler MA, Abbott KC, et al. Incidence, predictors, and associated outcomes of atrial fibrillation after kidney transplantation. Clin J Am Soc Nephrol. 2006;1:288-96.
6. Ramanathan V, Goral S, Tanriover B, et al. Screening asymptomatic diabetic patients for coronary artery disease prior to renal transplantation. Transplantation. 2005;79:1453-8. (Pubitemid 40734812)
7. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 Guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Circulation. 2007;116:1971-96
8. Hendel RC, Berman DS, Di Carli MF, et al. ACCF/ASNC/ACR/AHA/ASE/SCCT/ SCMR/SNM 2009 appropriate use criteria for cardiac radionuclide imaging: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the American Society of Nuclear Cardiology, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the Society of Cardiovascular Computed Tomography, the Society for Cardiovascular Magnetic Resonance, and the Society of Nuclear Medicine. Circulation. 2009;119:e561-87.
9. Poldermans D, Schouten O, Vidakovic R, et al. A clinical randomized trial to evaluate the safety of a noninvasive approach in high-risk patients undergoing major vascular surgery: the DECREASE-V Pilot Study. J Am Coll Cardiol. 2007;49:1763-9. (Pubitemid 46617863)
10. McFalls EO, Ward HB, Moritz TE, et al. Coronary-artery revascularization before elective major vascular surgery. N Engl J Med. 2004;351: 2795-804. (Pubitemid 40051903)
11. Schouten O, van Kuijk JP, Flu WJ, et al. Long-term outcome of prophylactic coronary revascularization in cardiac high-risk patients undergoing major vascular surgery (from the randomized DECREASE-V Pilot Study). Am J Cardiol. 2009;103:897-901.
12. K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005;45(suppl 3):S1-153.
13. Abbud-Filho M, Adams PL, Alberu J, et al. A report of the Lisbon Conference on the care of the kidney transplant recipient. Transplantation. 2007;83(suppl):S1-22. (Pubitemid 46653086)
14. Kasiske BL, Cangro CB, Hariharan S, et al. The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant. 2001;1(suppl 2):3-95.
15. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section I: evaluation, selection and preparation of the potential transplant recipient. I.5. Risk factors/relative contra-indications. Nephrol Dial Transplant. 2000;15(suppl 7):3-38.
16. Ferreira SR, Moises VA, Tavares A, Pacheco-Silva A. Cardiovascular effects of successful renal transplantation: a 1-year sequential study of left ventricular morphology and function, and 24-hour blood pressure profile. Transplantation. 2002;74:1580-7. (Pubitemid 36014232)
17. Ramos EL, Kasiske BL, Alexander SR, et al. The evaluation of candidates for renal transplantation: the current practice of U.S. transplant centers. Transplantation. 1994;57:490-7. (Pubitemid 24075790)
18. Danovitch GM, Hariharan S, Pirsch JD, et al. Management of the waiting list for cadaveric kidney transplants: report of a survey and recommendations by the Clinical Practice Guidelines Committee of the American Society of Transplantation. J Am Soc Nephrol. 2002;13: 528-35. (Pubitemid 34106297)
19. Zarifian A, O'Rourke M. Managing the kidney waiting list. Prog Transplant. 2006;16:242-6.
20. Lentine KL, Schnitzler MA, Brennan DC, et al. Cardiac evaluation before kidney transplantation: a practice patterns analysis in Medicareinsured dialysis patients. Clin J Am Soc Nephrol. 2008;3:1115-24.
21. Weng FL, Joffe MM, Feldman HI, Mange KC. Rates of completion of the medical evaluation for renal transplantation. Am J Kidney Dis. 2005;46:734-45. (Pubitemid 41383952)
22. Kressin NR, Petersen LA. Racial differences in the use of invasive cardiovascular procedures: review of the literature and prescription for future research. Ann Intern Med. 2001;135:352-66. (Pubitemid 32823242)
23. Friedman S, Palac R, Chobanian M, Costa S. A Call to Action: variability in guidelines for cardiac evaluation prior to renal transplantation. Clin J Am Soc Nephrol. 2011;6:1185-91.
24. Kasiske BL, Malik MA, Herzog CA. Risk-stratified screening for ischemic heart disease in kidney transplant candidates. Transplantation. 2005; 80:815-20. (Pubitemid 41443765)
25. Lewis MS, Wilson RA, Walker K, et al. Factors in cardiac risk stratification of candidates for renal transplant. J Cardiovasc Risk. 1999;6: 251-5. (Pubitemid 29421887)
26. Patel AD, Abo-Auda WS, Davis JM, et al. Prognostic value of myocardial perfusion imaging in predicting outcome after renal transplantation. Am J Cardiol. 2003;92:146-51. (Pubitemid 36835962)
27. Patel RK, Mark PB, Johnston N, et al. Prognostic value of cardiovascular screening in potential renal transplant recipients: a single-center prospective observational study. Am J Transplant. 2008;8:1673-83.
28. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356: 1503-16. (Pubitemid 46588415)
29. Sedlis SP, Jurkovitz CT, Hartigan PM, et al. Optimal medical therapy with or without percutaneous coronary intervention for patients with stable coronary artery disease and chronic kidney disease. Am J Cardiol. 2009;104:1647-53.
30. Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation. 2004;110: e340-437.
31. Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124:e652-735.
32. Port FK, Wolfe RA, Mauger EA, et al. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA. 1993;270:1339-43. (Pubitemid 23267894)
33. Merion RM, Ashby VB, Wolfe RA, et al. Deceased-donor characteristics and the survival benefit of kidney transplantation. JAMA. 2005; 294:2726-33. (Pubitemid 41770102)
34. Gill JS, Tonelli M, Johnson N, et al. The impact of waiting time and comorbid conditions on the survival benefit of kidney transplantation. Kidney Int. 2005;68:2345-51. (Pubitemid 43117814)
35. Jeloka TK, Ross H, Smith R, et al. Renal transplant outcome in highcardiovascular risk recipients. Clin Transplant. 2007;21:609-14. (Pubitemid 47399424)
36. Frank SM, Beattie C, Christopherson R, et al. Perioperative rate-related silent myocardial ischemia and postoperative death. J Clin Anesth. 1990;2:326-31. (Pubitemid 20326175)
37. Landesberg G, Luria MH, Cotev S, et al. Importance of long-duration postoperative ST-segment depression in cardiac morbidity after vascular surgery. Lancet. 1993;341:715-9. (Pubitemid 23085177)
38. Landesberg G, Mosseri M, Wolf Y, et al. Perioperative myocardial ischemia and infarction: identification by continuous 12-lead electrocardiogram with online ST-segment monitoring. Anesthesiology. 2002;96: 264-70. (Pubitemid 34121731)
39. Fleisher LA, Nelson AH, Rosenbaum SH. Postoperative myocardial ischemia: etiology of cardiac morbidity or manifestation of underlying disease? J Clin Anesth. 1995;7:97-102.
40. Fuster V, Stein B, Ambrose JA, et al. Atherosclerotic plaque rupture and thrombosis: evolving concepts. Circulation. 1990;82(suppl):II47-59.
41. Tuman KJ, McCarthy RJ, March RJ, et al. Effects of epidural anesthesia and analgesia on coagulation and outcome after major vascular surgery. Anesth Analg. 1991;73:696-704.
42. Ellis SG, Hertzer NR, Young JR, Brener S. Angiographic correlates of cardiac death and myocardial infarction complicating major nonthoracic vascular surgery. Am J Cardiol. 1996;77:1126-8. (Pubitemid 126334755)
43. Dawood MM, Gutpa DK, Southern J, et al. Pathology of fatal perioperative myocardial infarction: implications regarding pathophysiology and prevention. Int J Cardiol. 1996;57:37-44. (Pubitemid 26388825)
44. Herzog CA, Littrell K, Arko C, et al. Clinical characteristics of dialysis patients with acute myocardial infarction in the United States: a collaborative project of the United States Renal Data System and the National Registry of Myocardial Infarction. Circulation. 2007;116:1465-72. (Pubitemid 47480637)
45. Sosnov J, Lessard D, Goldberg RJ, et al. Differential symptoms of acute myocardial infarction in patients with kidney disease: a community-wide perspective. Am J Kidney Dis. 2006;47:378-84. (Pubitemid 43255170)
46. Almehmi A, Broce M, Wetmore JB. Silent myocardiac ischemia is more prevalent in CKD patients undergoing multi-vessel coronary angioplasty abstract. J Am Soc Nephrol. 2009;20(suppl):370A.
47. Young LH, Wackers FJ, Chyun DA, et al. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA. 2009;301:1547-55.
48. Reilly DF, McNeely MJ, Doerner D, et al. Self-reported exercise tolerance and the risk of serious perioperative complications. Arch Intern Med. 1999;159:2185-92. (Pubitemid 29483158)
49. Bennett WM, Kloster F, Rosch J, et al. Natural history of asymptomatic coronary arteriographic lesions in diabetic patients with end-stage renal disease. Am J Med. 1978;65:779-84. (Pubitemid 9067005)
50. Weinrauch L, D'Elia JA, Healy RW, et al. Asymptomatic coronary artery disease: angiographic assessment of diabetics evaluated for renal transplantation. Circulation. 1978;58:1184-90. (Pubitemid 9092002)
51. Braun WE, Phillips DF, Vidt DG, et al. Coronary artery disease in 100 diabetics with end-stage renal failure. Transplant Proc. 1984;16:603-7. (Pubitemid 14065531)
52. Lorber MI, Van Buren CT, Flechner SM, et al. Pretransplant coronary arteriography for diabetic renal transplant recipients. Transplant Proc. 1987;19(pt 2):1539-41. (Pubitemid 17026920)
53. Manske CL, Wilson RF, Wang Y, Thomas W. Prevalence of, and risk factors for, angiographically determined coronary artery disease in type I-diabetic patients with nephropathy. Arch Intern Med. 1992;152: 2450-5.
54. Ohtake T, Kobayashi S, Moriya H, et al. High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy: an angiographic examination. J Am Soc Nephrol. 2005;16:1141-8. (Pubitemid 41710326)
55. Sharma R, Pellerin D, Gaze DC, et al. Dobutamine stress echocardiography and the resting but not exercise electrocardiograph predict severe coronary artery disease in renal transplant candidates. Nephrol Dial Transplant. 2005;20:2207-14. (Pubitemid 41510099)
56. De Lima JJ, Sabbaga E, Vieira ML, et al. Coronary angiography is the best predictor of events in renal transplant candidates compared with noninvasive testing. Hypertension. 2003;42:263-8. (Pubitemid 37093471)
57. Charytan D, Kuntz RE, Mauri L, DeFilippi C. Distribution of coronary artery disease and relation to mortality in asymptomatic hemodialysis patients. Am J Kidney Dis. 2007;49:409-16.
58. Gowdak LH, de Paula FJ, Cesar LA, et al. Screening for significant coronary artery disease in high-risk renal transplant candidates. Coron Artery Dis. 2007;18:553-8. (Pubitemid 47556387)
59. Gowdak LH, de Paula FJ, Cesar LA, et al. Diabetes and coronary artery disease impose similar cardiovascular morbidity and mortality on renal transplant candidates. Nephrol Dial Transplant. 2007;22:1456-61. (Pubitemid 47078650)
60. Hage FG, Smalheiser S, Zoghbi GJ, et al. Predictors of survival in patients with end-stage renal disease evaluated for kidney transplantation. Am J Cardiol. 2007;100:1020-5. (Pubitemid 47368111)
61. Hickson LJ, Cosio FG, El-Zoghby ZM, et al. Survival of patients on the kidney transplant wait list: relationship to cardiac troponin T. Am J Transplant. 2008;8:2352-9.
62. Lentine KL, Hurst FP, Jindal RM, et al. Cardiovascular risk assessment among potential kidney transplant candidates: approaches and controversies. Am J Kidney Dis. 2010;55:152-67.
63. Marwick TH, Steinmuller DR, Underwood DA, et al. Ineffectiveness of dipyridamole single-photon emission computed tomography thallium imaging as a screening technique for coronary artery disease in patients with end-stage renal failure. Transplantation. 1990;49:100-3. (Pubitemid 20051594)
64. Boudreau RJ, Strony JT, duCret RP, et al. Perfusion thallium imaging of type I diabetes patients with end stage renal disease: comparison of oral and intravenous dipyridamole administration. Radiology. 1990;175: 103-5. (Pubitemid 20108548)
65. Vandenberg BF, Rossen JD, Grover-McKay M, et al. Evaluation of diabetic patients for renal and pancreas transplantation: noninvasive screening for coronary artery disease using radionuclide methods. Transplantation. 1996;62:1230-5. (Pubitemid 27008545)
66. Dahan M, Viron BM, Faraggi M, et al. Diagnostic accuracy and prognostic value of combined dipyridamole-exercise thallium imaging in hemodialysis patients. Kidney Int. 1998;54:255-62. (Pubitemid 28288042)
67. Herzog CA, Marwick TH, Pheley AM, et al. Dobutamine stress echocardiography for the detection of significant coronary artery disease in renal transplant candidates. Am J Kidney Dis. 1999;33:1080-90. (Pubitemid 29252678)
68. Worthley MI, Unger SA, Mathew TH, et al. Usefulness of tachycardicstress perfusion imaging to predict coronary artery disease in high-risk patients with chronic renal failure. Am J Cardiol. 2003;92:1318-20. (Pubitemid 37431142)
69. Ferreira PA, de Lima VC, Campos Filho O, et al. Feasibility, safety and accuracy of dobutamine/atropine stress echocardiography for the detection of coronary artery disease in renal transplant candidates. Arq Bras Cardiol. 2007;88:45-51.
70. Ragosta M, Samady H, Isaacs RB, et al. Coronary flow reserve abnormalities in patients with diabetes mellitus who have end-stage renal disease and normal epicardial coronary arteries. Am Heart J. 2004;147: 1017-23. (Pubitemid 38880957)
71. Morrow CE, Schwartz JS, Sutherland DE, et al. Predictive value of thallium stress testing for coronary and cardiovascular events in uremic diabetic patients before renal transplantation. Am J Surg. 1983;146: 331-5. (Pubitemid 13001740)
72. Reis G, Marcovitz PA, Leichtman AB, et al. Usefulness of dobutamine stress echocardiography in detecting coronary artery disease in end-stage renal disease. Am J Cardiol. 1995;75:707-10.
73. Bates JR, Sawada SG, Segar DS, et al. Evaluation using dobutamine stress echocardiography in patients with insulin-dependent diabetes mellitus before kidney and/or pancreas transplantation. Am J Cardiol. 1996;77:175-9. (Pubitemid 26032606)
74. Tita C, Karthikeyan V, Stroe A, et al. Stress echocardiography for risk stratification in patients with end-stage renal disease undergoing renal transplantation. J Am Soc Echocardiogr. 2008;21:321-6.
75. Marwick TH, Lauer MS, Lobo A, et al. Use of dobutamine echocardiography for cardiac risk stratification of patients with chronic renal failure. J Intern Med. 1998;244:155-61. (Pubitemid 28364801)
76. Rakhit DJ, Armstrong KA, Beller E, et al. Risk stratification of patients with chronic kidney disease: results of screening strategies incorporating clinical risk scoring and dobutamine stress echocardiography. Am Heart J. 2006;152:363-70. (Pubitemid 44093400)
77. Rabbat CG, Treleaven DJ, Russell JD, et al. Prognostic value of myocardial perfusion studies in patients with end-stage renal disease assessed for kidney or kidney-pancreas transplantation: a meta-analysis. J Am Soc Nephrol. 2003;14:431-9. (Pubitemid 36150867)
78. Bergeron S, Hillis GS, Haugen EN, et al. Prognostic value of dobutamine stress echocardiography in patients with chronic kidney disease. Am Heart J. 2007;153:385-91. (Pubitemid 46328755)
79. Wong CF, Little MA, Vinjamuri S, et al. Technetium myocardial perfusion scanning in prerenal transplant evaluation in the United Kingdom. Transplant Proc. 2008;40:1324-8. (Pubitemid 351853189)
80. Consensus development conference on the diagnosis of coronary heart disease in people with diabetes: 10-11 February 1998, Miami, Florida: American Diabetes Association. Diabetes Care. 1998;21:1551-9.
81. Scognamiglio R, Negut C, Ramondo A, et al. Detection of coronary artery disease in asymptomatic patients with type 2 diabetes mellitus. J Am Coll Cardiol. 2006;47:65-71. (Pubitemid 43005166)
82. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339: 229-34. (Pubitemid 28350165)
83. Diamond GA, Kaul S, Shah PK. Screen testing cardiovascular prevention in asymptomatic diabetic patients. J Am Coll Cardiol. 2007;49: 1915-7. (Pubitemid 46694281)
84. Aalten J, Hoogeveen EK, Roodnat JI, et al. Associations between prekidney-transplant risk factors and post-transplant cardiovascular events and death. Transpl Int. 2008;21:985-91.
85. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol. 2000; 11:1735-43.
86. Ducloux D, Kazory A, Chalopin JM. Predicting coronary heart disease in renal transplant recipients: a prospective study. Kidney Int. 2004;66: 441-7. (Pubitemid 38870123)
87. Kiberd B, Panek R. Cardiovascular outcomes in the outpatient kidney transplant clinic: the Framingham risk score revisited. Clin J Am Soc Nephrol. 2008;3:822-8.
88. Gaston RS, Danovitch GM, Adams PL, et al. The report of a national conference on the wait list for kidney transplantation. Am J Transplant. 2003;3:775-85. (Pubitemid 36827899)
89. Inoguchi T, Yamashita T, Umeda F, et al. High incidence of silent myocardial ischemia in elderly patients with non insulin-dependent diabetes mellitus. Diabetes Res Clin Pract. 2000;47:37-44.
90. Hachamovitch R, Hayes S, Friedman JD, et al. Determinants of risk and its temporal variation in patients with normal stress myocardial perfusion scans: what is the warranty period of a normal scan? J Am Coll Cardiol. 2003;41:1329-40. (Pubitemid 36438995)
91. Hakeem A, Bhatti S, Dillie KS, et al. Predictive value of myocardial perfusion single-photon emission computed tomography and the impact of renal function on cardiac death. Circulation. 2008;118:2540-9.
92. Rakhit DJ, Marwick TH, Armstrong KA, et al. Effect of aggressive risk factor modification on cardiac events and myocardial ischaemia in patients with chronic kidney disease. Heart. 2006;92:1402-8. (Pubitemid 44578827)
93. Gill JS, Ma I, Landsberg D, et al. Cardiovascular events and investigation in patients who are awaiting cadaveric kidney transplantation. J Am Soc Nephrol. 2005;16:808-16. (Pubitemid 41725118)
94. Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 1995;47:186-92.
95. Siedlecki A, Foushee M, Curtis JJ, et al. The impact of left ventricular systolic dysfunction on survival after renal transplantation. Transplantation. 2007;84:1610-7.
96. de Mattos AM, Siedlecki A, Gaston RS, et al. Systolic dysfunction portends increased mortality among those waiting for renal transplant. J Am Soc Nephrol. 2008;19:1191-6.
97. Yamada S, Ishii H, Takahashi H, et al. Prognostic value of reduced left ventricular ejection fraction at start of hemodialysis therapy on cardiovascular and all-cause mortality in end-stage renal disease patients. Clin J Am Soc Nephrol. 2010;5:1793-8.
98. Cice G, Ferrara L, D'Andrea A, et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol. 2003;41:1438-44. (Pubitemid 36543357)
99. Wali RK, Wang GS, Gottlieb SS, et al. Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease. J Am Coll Cardiol. 2005;45: 1051-60. (Pubitemid 40432438)
100. Stokkel M, Duchateau CS, Jukema W, de Fijter HW. Noninvasive assessment of left ventricular function prior to and 6 months after renal transplantation. Transplant Proc. 2007;39:3159-62. (Pubitemid 350251458)
101. Lentine KL, Xiao H, Brennan DC, et al. The impact of kidney transplantation on heart failure risk varies with candidate body mass index. Am Heart J. 2009;158:972-82.
102. Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease). Circulation. 2008;118:e523-661.
103. Abbott KC, Hshieh P, Cruess D, et al. Hospitalized valvular heart disease in patients on renal transplant waiting list: incidence, clinical correlates and outcomes. Clin Nephrol. 2003;59:79-87. (Pubitemid 36221742)
104. Umana E, Ahmed W, Alpert MA. Valvular and perivalvular abnormalities in end-stage renal disease. Am J Med Sci. 2003;325:237-42. (Pubitemid 36437996)
105. Mizutani K, Naruko T, Komatsu R, Ueda M. Enhanced expression of neopterin in accumulated macrophages at aortic valve stenosis in patients with hemodialysis abstract. J Am Coll Cardiol. 2011; 57:E1303.
106. Melchor JL, Gracida C, Orihuela O. Improvement of mitral dysfunction after kidney transplantation. Transplant Proc. 2002;34:396-7. (Pubitemid 34311726)
107. ACC/AHA guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association: Task Force on Practice Guidelines (Committee on Management of Patients With Valvular Heart Disease). J Am Coll Cardiol. 1998;32:1486-588.
108. Herzog CA, Ma JZ, Collins AJ. Long-term survival of dialysis patients in the United States with prosthetic heart valves: should ACC/AHA practice guidelines on valve selection be modified? Circulation. 2002; 105:1336-1341. (Pubitemid 34260425)
109. Sharma A, Gilbertson DT, Herzog CA. Survival of kidney transplantation patients in the United States after cardiac valve replacement. Circulation. 2010;121:2733-9.
110. Zlotnick DM, Axelrod DA, Chobanian MC, et al. Non-invasive detection of pulmonary hypertension prior to renal transplantation is a predictor of increased risk for early graft dysfunction. Nephrol Dial Transplant. 2010;25:3090-6.
111. Issa N, Krowka MJ, Griffin MD, et al. Pulmonary hypertension is associated with reduced patient survival after kidney transplantation. Transplantation. 2008;86:1384-8.
112. McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation. 2006;114:1417-31. (Pubitemid 44454562)
113. Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010;23:685-713.
114. Rakhit DJ, Zhang XH, Leano R, et al. Prognostic role of subclinical left ventricular abnormalities and impact of transplantation in chronic kidney disease. Am Heart J. 2007;153:656-64. (Pubitemid 46440691)
115. Abe S, Yoshizawa M, Nakanishi N, et al. Electrocardiographic abnormalities in patients receiving hemodialysis. Am Heart J. 1996;131: 1137-44. (Pubitemid 26176992)
116. Rajagopalan N, Miller TD, Hodge DO, et al. Identifying high-risk asymptomatic diabetic patients who are candidates for screening stress single-photon emission computed tomography imaging. J Am Coll Cardiol. 2005;45:43-9. (Pubitemid 40063548)
117. Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac disease: the present and the future. J Am Coll Cardiol. 2006;48:1-11. (Pubitemid 44202476)
118. Khan NA, Hemmelgarn BR, Tonelli M, et al. Prognostic value of troponin T and I among asymptomatic patients with end-stage renal disease: a meta-analysis published correction appears in Circulation. 2006;113:e742. Circulation. 2005;112:3088-96. (Pubitemid 43113440)
119. Sharma R, Gaze DC, Pellerin D, et al. Ischemia-modified albumin predicts mortality in ESRD. Am J Kidney Dis. 2006;47:493-502. (Pubitemid 43255184)
120. Connolly GM, Cunningham R, McNamee PT, et al. Troponin T is an independent predictor of mortality in renal transplant recipients. Nephrol Dial Transplant. 2008;23:1019-25. (Pubitemid 351767577)
121. Hickson LT, El-Zoghby ZM, Lorenz EC, et al. Patient survival after kidney transplantation: relationship to pretransplant cardiac troponin T levels. Am J Transplant. 2009;9:1354-61.
122. Budoff MJ, Shaw LJ, Liu ST, et al. Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. J Am Coll Cardiol. 2007;49:1860-70. (Pubitemid 46661110)
123. Raggi P, Boulay A, Chasan-Taber S, et al. Cardiac calcification in adult hemodialysis patients: a link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol. 2002;39:695-701. (Pubitemid 34158168)
124. Braun J, Oldendorf M, Moshage W, et al. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis. 1996;27:394-401. (Pubitemid 26075849)
125. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342:1478-83. (Pubitemid 30318271)
126. Oh J, Wunsch R, Turzer M, et al. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation. 2002;106:100-5. (Pubitemid 34747448)
127. Matsuoka M, Iseki K, Tamashiro M, et al. Impact of high coronary artery calcification score (CACS) on survival in patients on chronic hemodialysis. Clin Exp Nephrol. 2004;8:54-8. (Pubitemid 38508656)
128. Greenland P, Bonow RO, Brundage BH, et al. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography). Circulation. 2007;115:402-26. (Pubitemid 46148515)
129. Haydar AA, Hujairi NM, Covic AA, et al. Coronary artery calcification is related to coronary atherosclerosis in chronic renal disease patients: a study comparing EBCT-generated coronary artery calcium scores and coronary angiography. Nephrol Dial Transplant. 2004;19:2307-12. (Pubitemid 39214126)
130. Sharples EJ, Pereira D, Summers S, et al. Coronary artery calcification measured with electron-beam computerized tomography correlates poorly with coronary artery angiography in dialysis patients. Am J Kidney Dis. 2004;43:313-9. (Pubitemid 38146330)
131. Tong LL, Mehrotra R, Shavelle DM, et al. Poor correlation between coronary artery calcification and obstructive coronary artery disease in an end-stage renal disease patient. Hemodial Int. 2008;12:16-22. (Pubitemid 351247371)
132. Shroff RC, McNair R, Figg N, et al. Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation. 2008;118:1748-57.
133. Vanhoenacker PK, Heijenbrok-Kal MH, Van Heste R, et al. Diagnostic performance of multidetector CT angiography for assessment of coronary artery disease: meta-analysis. Radiology. 2007;244:419-28. (Pubitemid 47080873)
134. Meijboom WB, Weustink AC, Pugliese F, et al. Comparison of diagnostic accuracy of 64-slice computed tomography coronary angiography in women versus men with angina pectoris. Am J Cardiol. 2007;100: 1532-7. (Pubitemid 350050861)
135. Taylor AJ, Cerqueira M, Hodgson JM, et al. ACCF/SCCT/ACR/AHA/ASE/ASNC/ NASCI/SCAI/SCMR 2010 appropriate use criteria for cardiac computed tomography: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the Society of Cardiovascular Computed Tomography, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the American Society of Nuclear Cardiology, the North American Society for Cardiovascular Imaging, the Society for Cardiovascular Angiography and Interventions, and the Society for Cardiovascular Magnetic Resonance. Circulation. 2010;122:e525-55.
136. Manske CL, Wang Y, Rector T, et al. Coronary revascularisation in insulin-dependent diabetic patients with chronic renal failure. Lancet. 1992;340:998-1002.
137. Kumar N, Baker CS, Chan K, et al. Cardiac survival after pre-emptive coronary angiography in transplant patients and those awaiting transplantation. Clin J Am Soc Nephrol. 2011;6:1912-9.
138. Garcia S, Moritz TE, Ward HB, et al. Usefulness of revascularization of patients with multivessel coronary artery disease before elective vascular surgery for abdominal aortic and peripheral occlusive disease. Am J Cardiol. 2008;102:809-13.
139. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation. 2006;113:156-75. (Pubitemid 43958502)
140. Anderson JL, Adams CD, Antman EM, et al. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;123:e426-579.
141. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011;124: e574-651.
142. Szczech LA, Reddan DN, Owen WF, et al. Differential survival after coronary revascularization procedures among patients with renal insufficiency. Kidney Int. 2001;60:292-9. (Pubitemid 32587567)
143. Reddan DN, Szczech LA, Tuttle RH, et al. Chronic kidney disease, mortality, and treatment strategies among patients with clinically significant coronary artery disease. J Am Soc Nephrol. 2003;14:2373-80. (Pubitemid 37052385)
144. Hemmelgarn BR, Southern D, Culleton BF, et al. Survival after coronary revascularization among patients with kidney disease. Circulation. 2004;110:1890-5. (Pubitemid 39331897)
145. Herzog CA, Ma JZ, Collins AJ. Long-term outcome of renal transplant recipients in the United States after coronary revascularization procedures. Circulation. 2004;109:2866-71. (Pubitemid 38780300)
146. Herzog CA, Solid CA. Long-term survival of U.S. dialysis patients after surgical bypass or percutaneous coronary stent placement in the drugeluting stent era abstract. J Am Soc Nephrol. 2008;19(suppl):11A.
147. Ashrith G, Elayda MA, Wilson JM. Revascularization options in patients with chronic kidney disease. Tex Heart Inst J. 2010;37:9-18.
148. Flaherty JD, Davidson CJ. Diabetes and coronary revascularization. JAMA. 2005;293(12):1501-8. (Pubitemid 40393296)
149. Hlatky MA, Boothroyd DB, Bravata DM, et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet. 2009;373:1190-7.
150. Malenka DJ, Leavitt BJ, Hearne MJ, et al. Comparing long-term survival of patients with multivessel coronary disease after CABG or PCI: analysis of BARI-like patients in northern New England. Circulation. 2005;112(suppl):I371-6. (Pubitemid 41266701)
151. McCullough PA, Adam A, Becker CR, et al. Risk prediction of contrastinduced nephropathy. Am J Cardiol. 2006;98:27K-36K.
152. Tan N, Liu Y, Zhou YL, et al. Contrast medium volume to creatinine clearance ratio: a predictor of contrast-induced nephropathy in the first 72 hours following percutaneous coronary intervention. Cathet Cardiovasc Intervent. 2012;79:70-5.
153. Kumar N, Dahri L, Brown W, et al. Effect of elective coronary angiography on glomerular filtration rate in patients with advanced chronic kidney disease. Clin J Am Soc Nephrol. 2009;4:1907-13.
154. Lorenz EC, Stegall MD, Cosio FG, et al. The effect of coronary angiography on renal function in preemptive renal transplant candidates. Clin Transplant. 2011;25:594-9.
155. Brilakis ES, Orford JL, Fasseas P, et al. Outcome of patients undergoing balloon angioplasty in the two months prior to noncardiac surgery. Am J Cardiol. 2005;96:512-4. (Pubitemid 41132765)
156. Wilson SH, Rihal CS, Bell MR, et al. Timing of coronary stent thrombosis in patients treated with ticlopidine and aspirin. Am J Cardiol. 1999;83:1006-11. (Pubitemid 29162781)
157. Berger PB, Bell MR, Hasdai D, et al. Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement. Circulation. 1999;99:248-53. (Pubitemid 29056367)
158. Nuttall GA, Brown MJ, Stombaugh JW, et al. Time and cardiac risk of surgery after bare-metal stent percutaneous coronary intervention. Anesthesiology. 2008;109:588-95.
159. Rabbitts JA, Nuttall GA, Brown MJ, et al. Cardiac risk of noncardiac surgery after percutaneous coronary intervention with drug-eluting stents. Anesthesiology. 2008;109:596-604.
160. van Kuijk JP, Flu WJ, Schouten O, et al. Timing of noncardiac surgery after coronary artery stenting with bare metal or drug-eluting stents. Am J Cardiol. 2009;104:1229-34.
161. Anwaruddin S, Askari AT, Saudye H, et al. Characterization of postoperative risk associated with prior drug-eluting stent use. JACC Cardiovasc Interv. 2009;2:542-9.
162. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344-51. (Pubitemid 46685903)
163. Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol. 2007;49:734-9. (Pubitemid 46210116)
164. Eisenberg MJ, Richard PR, Libersan D, Filion KB. Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents. Circulation. 2009;119:1634-42.
165. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(suppl 1):S1-290.
166. Levin NW, Kotanko P, Eckardt KU, et al. Blood pressure in chronic kidney disease stage 5D: report from a Kidney Disease: Improving Global Outcomes controversies conference. Kidney Int. 2010;77: 273-84.
167. Davenport A, Cox C, Thuraisingham R. Achieving blood pressure targets during dialysis improves control but increases intradialytic hypotension. Kidney Int. 2008;73:759-64. (Pubitemid 351323255)
168. Agarwal R, Metiku T, Tegegne GG, et al. Diagnosing hypertension by intradialytic blood pressure recordings. Clin J Am Soc Nephrol. 2008; 3:1364-72.
169. Agarwal R, Peixoto AJ, Santos SF, Zoccali C. Pre-and postdialysis blood pressures are imprecise estimates of interdialytic ambulatory blood pressure. Clin J Am Soc Nephrol. 2006;1:389-98.
170. Agarwal R, Andersen MJ, Bishu K, Saha C. Home blood pressure monitoring improves the diagnosis of hypertension in hemodialysis patients. Kidney Int. 2006;69:900-6.
171. Agarwal R, Brim NJ, Mahenthiran J, et al. Out-of-hemodialysis-unit blood pressure is a superior determinant of left ventricular hypertrophy. Hypertension. 2006;47:62-8. (Pubitemid 43180109)
172. Alborzi P, Patel N, Agarwal R. Home blood pressures are of greater prognostic value than hemodialysis unit recordings. Clin J Am Soc Nephrol. 2007;2:1228-34.
173. Agarwal R, Andersen MJ. Prognostic importance of clinic and home blood pressure recordings in patients with chronic kidney disease. Kidney Int. 2006;69:406-11. (Pubitemid 43323095)
174. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003;63:793-808. (Pubitemid 36315558)
175. Heerspink HJ, Ninomiya T, Zoungas S, et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2009;373:1009-15.
176. Agarwal R, Alborzi P, Satyan S, Light RP. Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trial. Hypertension. 2009;53:500-7.
177. Berl T, Hunsicker LG, Lewis JB, et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med. 2003;138:542-9.
178. Mann JF, Gerstein HC, Pogue J, et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001;134:629-36. (Pubitemid 32322240)
179. Zannad F, Kessler M, Lehert P, et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int. 2006;70:1318-24. (Pubitemid 44435184)
180. Suzuki H, Kanno Y, Sugahara S, et al. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Am J Kidney Dis. 2008;52: 501-6.
181. Collins AJ, Foley R, Herzog C, et al. Excerpts from the United States Renal Data System 2007 annual data report. Am J Kidney Dis. 2008; 51(suppl 1):S1-320.
182. Culleton BF, Walsh M, Klarenbach SW, et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA. 2007; 298:1291-9. (Pubitemid 47443343)
183. Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis. 2003;41(suppl 3):I-IV, S1-91.
184. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 2003;289:2560-71.
185. Avram MM, Bonomini LV, Sreedhara R, Mittman N. Predictive value of nutritional markers (albumin, creatinine, cholesterol, and hematocrit) for patients on dialysis for up to 30 years. Am J Kidney Dis. 1996;28: 910-7. (Pubitemid 26412089)
186. Iseki K, Yamazato M, Tozawa M, Takishita S. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int. 2002;61:1887-93. (Pubitemid 34437945)
187. Kalantar-Zadeh K, Kopple JD, Block G, Humphreys MH. A malnutrition-inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients. Am J Kidney Dis. 2001;38: 1251-63. (Pubitemid 34193111)
188. Gamba G, Mejia JL, Saldivar S, et al. Death risk in CAPD patients: the predictive value of the initial clinical and laboratory variables. Nephron. 1993;65:23-7.
189. Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA. 2004;291:451-9. (Pubitemid 38129749)
190. Seliger SL, Weiss NS, Gillen DL, et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int. 2002;61:297-304. (Pubitemid 34075157)
191. Goldfarb-Rumyantzev AS, Habib AN, Baird BC, et al. The association of lipid-modifying medications with mortality in patients on long-term peritoneal dialysis. Am J Kidney Dis. 2007;50:791-802. (Pubitemid 47588556)
192. Mason NA, Bailie GR, Satayathum S, et al. HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis. 2005;45:119-26. (Pubitemid 40038052)
193. Robson R, Collins J, Johnson R, et al. Effects of simvastatin and enalapril on serum lipoprotein concentrations and left ventricular mass in patients on dialysis: the Perfect Study Collaborative Group. J Nephrol. 1997;10:33-40. (Pubitemid 27132478)
194. Chang JW, Yang WS, Min WK, et al. Effects of simvastatin on highsensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis. 2002;39:1213-7. (Pubitemid 34591937)
195. Harris KP, Wheeler DC, Chong CC. A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD. Kidney Int. 2002;61:1469-74. (Pubitemid 34304508)
196. Saltissi D, Morgan C, Rigby RJ, Westhuyzen J. Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. Am J Kidney Dis. 2002;39:283-90. (Pubitemid 34174250)
197. Lins RL, Matthys KE, Billiouw JM, et al. Lipid and apoprotein changes during atorvastatin up-titration in hemodialysis patients with hypercholesterolemia: a placebo-controlled study. Clin Nephrol. 2004;62:287-94. (Pubitemid 39386805)
198. Diepeveen SH, Verhoeven GW, Van Der Palen J, et al. Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial. J Intern Med. 2005;257: 438-45. (Pubitemid 40604548)
199. Baigent C, Landray M, Leaper C, et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis. 2005;45:473-84. (Pubitemid 40341326)
200. Ichihara A, Hayashi M, Ryuzaki M, et al. Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrol Dial Transplant. 2002;17:1513-7.
201. Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis. 2003;41(suppl 3):I-IV, S1-91.
202. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
203. Stegmayr BG, Brannstrom M, Bucht S, et al. Low-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study. Scand J Urol Nephrol. 2005;39:489-97. (Pubitemid 41722032)
204. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353: 238-48. (Pubitemid 41058323)
205. Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395-407.
206. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685-96. (Pubitemid 39140624)
207. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181-92.
208. Strippoli GF, Navaneethan SD, Johnson DW, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ. 2008;336:645-51. (Pubitemid 351481234)
209. Collins R, Armitage J, Parish S, et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363:757-67.
210. Welten GM, Chonchol M, Hoeks SE, et al. Beta-blockers improve outcomes in kidney disease patients having noncardiac vascular surgery. Kidney Int. 2007;72:1527-34. (Pubitemid 350197946)
211. Mangano DT, Layug EL, Wallace A, Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery: Multicenter Study of Perioperative Ischemia Research Group. N Engl J Med. 1996;335:1713-20. (Pubitemid 26399345)
212. Poldermans D, Boersma E, Bax JJ, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery: Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group see comments. N Engl J Med. 1999;341:1789-94.
213. Lindenauer PK, Pekow P, Wang K, et al. Perioperative beta-blocker therapy and mortality after major noncardiac surgery. N Engl J Med. 2005;353:349-61. (Pubitemid 41132339)
214. Yang H, Raymer K, Butler R, et al. The effects of perioperative betablockade: results of the Metoprolol after Vascular Surgery (MaVS) study, a randomized controlled trial. Am Heart J. 2006;152:983-90. (Pubitemid 44632958)
215. Juul AB, Wetterslev J, Gluud C, et al. Effect of perioperative beta blockade in patients with diabetes undergoing major non-cardiac surgery: randomised placebo controlled, blinded multicentre trial. BMJ. 2006;332:1482.
216. Devereaux PJ, Yang H, Yusuf S, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet. 2008;371:1839-47.
217. Dunkelgrun M, Boersma E, Schouten O, et al. Bisoprolol and fluvastatin for the reduction of perioperative cardiac mortality and myocardial infarction in intermediate-risk patients undergoing noncardiovascular surgery: a randomized controlled trial (DECREASE-IV). Ann Surg. 2009;249:921-6.
218. Fleisher LA, Beckman JA, Brown KA, et al. 2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery. Circulation. 2009;120:e169-276.
219. Ciapetti M, di Valvasone S, di Filippo A, et al. Low-dose dopamine in kidney transplantation. Transplant Proc. 2009;41:4165-8.
220. Schnuelle P, Gottmann U, Hoeger S, et al. Effects of donor pretreatment with dopamine on graft function after kidney transplantation: a randomized controlled trial. JAMA. 2009;302:1067-75.
221. Ruilope LM, Salvetti A, Jamerson K, et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) study. J Am Soc Nephrol. 2001;12: 218-25. (Pubitemid 32116363)
222. Jardine MJ, Ninomiya T, Perkovic V, et al. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol. 2010;56: 956-65.
223. Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol. 2003;42:201-8. (Pubitemid 36851405)
224. McCullough PA, Sandberg KR, Borzak S, et al. Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. Am Heart J. 2002;144:226-32. (Pubitemid 34879643)
225. Durazzo AE, Machado FS, Ikeoka DT, et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. J Vasc Surg. 2004;39:967-75.
226. Schouten O, Boersma E, Hoeks SE, et al. Fluvastatin and perioperative events in patients undergoing vascular surgery. N Engl J Med. 2009; 361:980-9.
227. Le Manach Y, Godet G, Coriat P, et al. The impact of postoperative discontinuation or continuation of chronic statin therapy on cardiac outcome after major vascular surgery. Anesth Analg. 2007;104: 1326-33. (Pubitemid 46795280)
228. Pittas AG, Siegel RD, Lau J. Insulin therapy for critically ill hospitalized patients: a meta-analysis of randomized controlled trials. Arch Intern Med. 2004;164:2005-11. (Pubitemid 39390557)
229. Gandhi GY, Murad MH, Flynn DN, et al. Effect of perioperative insulin infusion on surgical morbidity and mortality: systematic review and meta-analysis of randomized trials. Mayo Clin Proc. 2008;83:418-30. (Pubitemid 351536467)
230. Thomas G, Rojas MC, Epstein SK, et al. Insulin therapy and acute kidney injury in critically ill patients: a systematic review. Nephrol Dial Transplant. 2007;22:2849-55. (Pubitemid 350093459)
231. Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360: 1283-97.
232. Holdaas H, Fellstrom B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003;361:2024-31. (Pubitemid 36695044)
233. Holdaas H, Fellstrom B, Cole E, et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant. 2005;5:2929-36. (Pubitemid 43923954)
234. Jardine AG, Holdaas H, Fellstrom B, et al. Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study. Am J Transplant. 2004;4: 988-95. (Pubitemid 38745598)
235. Holdaas H, Fellstrom B, Jardine AG, et al. Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation. Nephrol Dial Transplant. 2005;20:974-80. (Pubitemid 40704036)
236. Martinez Hernandez BE, Persaud JW, Varghese Z, Moorhead JF. Low-dose simvastatin is safe in hyperlipidaemic renal transplant patients. Nephrol Dial Transplant. 1993;8:637-41. (Pubitemid 23231148)
237. Arnadottir M, Eriksson LO, Germershausen JI, Thysell H. Low-dose simvastatin is a well-tolerated and efficacious cholesterol-lowering agent in ciclosporin-treated kidney transplant recipients: double-blind, randomized, placebo-controlled study in 40 patients. Nephron. 1994;68: 57-62. (Pubitemid 24251189)
238. Lepre F, Rigby R, Hawley C, et al. A double-blind placebo controlled trial of simvastatin for the treatment of dyslipidaemia in renal allograft recipients. Clin Transplant. 1999;13:520-5. (Pubitemid 30011430)
239. Renders L, Mayer-Kadner I, Koch C, et al. Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients. Nephrol Dial Transplant. 2001;16:141-6. (Pubitemid 32051488)
240. Santos AF, Keitel E, Bittar AE, et al. Safety and efficacy of simvastatin for hyperlipidemia in renal transplant recipients: a double-blind, randomized, placebo-controlled study. Transplant Proc. 2001;33:1194-5. (Pubitemid 32237809)
241. Katznelson S, Wilkinson AH, Kobashigawa JA, et al. The effect of pravastatin on acute rejection after kidney transplantation: a pilot study. Transplantation. 1996;61:1469-74. (Pubitemid 26172708)
242. Tuncer M, Suleymanlar G, Ersoy FF, Yakupoglu G. Comparison of the effects of simvastatin and pravastatin on acute rejection episodes in renal transplant patients. Transplant Proc. 2000;32:622-5. (Pubitemid 30254431)
243. Kasiske BL, Heim-Duthoy KL, Singer GG, et al. The effects of lipidlowering agents on acute renal allograft rejection. Transplantation. 2001; 72:223-27. (Pubitemid 32729338)
244. Holdaas H, Jardine AG, Wheeler DC, et al. Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney Int. 2001;60:1990-7. (Pubitemid 33000006)
245. Sahu K, Sharma R, Gupta A, et al. Effect of lovastatin, an HMG CoA reductase inhibitor, on acute renal allograft rejection. Clin Transplant. 2001;15:173-5. (Pubitemid 32487443)
246. Seron D, Oppenheimer F, Pallardo LM, et al. Fluvastatin in the prevention of renal transplant vasculopathy: results of a prospective, randomized, double-blind, placebo-controlled trial. Transplantation. 2008; 86:82-7.
247. Hausberg M, Kosch M, Stam F, et al. Effect of fluvastatin on endothelium-dependent brachial artery vasodilation in patients after renal transplantation. Kidney Int. 2001;59:1473-9. (Pubitemid 32281237)
248. Cofan F, Gilabert R, Zambon D, et al. Effect of pravastatin treatment on the evolution of extracoronary atherosclerosis in renal transplant patients. Transplant Proc. 2002;34:384-8. (Pubitemid 34311722)
249. Kosch M, Barenbrock M, Suwelack B, et al. Effect of a 3-year therapy with the 3-hydroxy-3-methylglutaryl coenzyme A reductase-inhibitor fluvastatin on endothelial function and distensibility of large arteries in hypercholesterolemic renal transplant recipient. Am J Kidney Dis. 2003; 41:1088-96. (Pubitemid 36532144)
250. Asberg A, Holdaas H, Jardine AG, et al. Fluvastatin reduces atherogenic lipids without any effect on native endothelial function early after kidney transplantation. Clin Transplant. 2003;17:385-90. (Pubitemid 36958202)
251. Wiesbauer F, Heinze G, Mitterbauer C, et al. Statin use is associated with prolonged survival of renal transplant recipients. J Am Soc Nephrol. 2008;19:2211-8.
252. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-504. (Pubitemid 38477774)
253. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004;292: 1307-16. (Pubitemid 39223221)
254. Koren MJ, Hunninghake DB; ALLIANCE Investigators. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the ALLIANCE study. J Am Coll Cardiol. 2004;44:1772-9. (Pubitemid 39424074)
255. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-35. (Pubitemid 40471450)
256. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-207.
257. Puthenparumpil JJ, Keough-Ryan T, Kiberd M, et al. Treatment of hypercholesterolemia with ezetimibe in the kidney transplant population. Transplant Proc. 2005;37:1033-5. (Pubitemid 40590783)
258. Buchanan C, Smith L, Corbett J, et al. A retrospective analysis of ezetimibe treatment in renal transplant recipients. Am J Transplant. 2006;6:770-4. (Pubitemid 43345015)
259. Kohnle M, Pietruck F, Kribben A, et al. Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation. Am J Transplant. 2006;6:205-8. (Pubitemid 43382220)
260. Langone AJ, Chuang P. Ezetimibe in renal transplant patients with hyperlipidemia resistant to HMG-CoA reductase inhibitors. Transplantation. 2006;81:804-7.
261. Kasiske B, Cosio FG, Beto J, et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant. 2004;4(suppl 7):13-53. (Pubitemid 38436863)
262. Fellstrom B, Holdaas H, Jardine AG, et al. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. Kidney Int. 2004;66:1549-55. (Pubitemid 39298389)
263. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(suppl 3):S1-155.
264. Schrier RW, Arroyo V, Bernardi M, et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988;8:1151-7.
265. Murray KF, Carithers RL Jr; AASLD. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology. 2005;41: 1407-32. (Pubitemid 40770295)
266. McDonnell PJ, Toye PA, Hutchins GM. Primary pulmonary hypertension and cirrhosis: are they related? Am Rev Respir Dis. 1983;127: 437-41. (Pubitemid 13083742)
267. Auletta M, Oliviero U, Iasiuolo L, et al. Pulmonary hypertension associated with liver cirrhosis: an echocardiographic study. Angiology. 2000;51:1013-20.
268. Ramsay MA, Simpson BR, Nguyen AT, et al. Severe pulmonary hypertension in liver transplant candidates. Liver Transpl Surg. 1997;3: 494-500. (Pubitemid 27427898)
269. Krowka MJ, Mandell MS, Ramsay MA, et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the Multicenter Liver Transplant Database. Liver Transpl. 2004;10:174-82. (Pubitemid 38240114)
270. Swanson KL, Wiesner RH, Nyberg SL, et al. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups. Am J Transplant. 2008;8:2445-53.
271. Ashfaq M, Chinnakotla S, Rogers L, et al. The impact of treatment of portopulmonary hypertension on survival following liver transplantation. Am J Transplant. 2007;7:1258-64. (Pubitemid 46643089)
272. Colle IO, Moreau R, Godinho E, et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology. 2003;37:401-9. (Pubitemid 36152540)
273. Kim WR, Krowka MJ, Plevak DJ, et al. Accuracy of Doppler echocardiography in the assessment of pulmonary hypertension in liver transplant candidates. Liver Transpl. 2000;6:453-8. (Pubitemid 30489119)
274. Torregrosa M, Genesca J, Gonzalez A, et al. Role of Doppler echocardiography in the assessment of portopulmonary hypertension in liver transplantation candidates. Transplantation. 2001;71:572-4. (Pubitemid 32207211)
275. Cotton CL, Gandhi S, Vaitkus PT, et al. Role of echocardiography in detecting portopulmonary hypertension in liver transplant candidates. Liver Transpl. 2002;8:1051-4. (Pubitemid 35363632)
276. Hoeper MM, Krowka MJ, Strassburg CP. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet. 2004;363:1461-8. (Pubitemid 38586724)
277. Porres-Aguilar M, Zuckerman MJ, Figueroa-Casas JB, Krowka MJ. Portopulmonary hypertension: state of the art. Ann Hepatol. 2008;7: 321-30.
278. Abbas AE, Fortuin FD, Schiller NB, et al. A simple method for noninvasive estimation of pulmonary vascular resistance. J Am Coll Cardiol. 2003;41:1021-7. (Pubitemid 36315548)
279. Rollan MJ, Munoz AC, Perez T, Bratos JL. Value of contrast echocardiography for the diagnosis of hepatopulmonary syndrome. Eur J Echocardiogr. 2007;8:408-10. (Pubitemid 47338276)
280. Vedrinne JM, Duperret S, Bizollon T, et al. Comparison of transesophageal and transthoracic contrast echocardiography for detection of an intrapulmonary shunt in liver disease. Chest. 1997;111:1236-40. (Pubitemid 27200077)
281. Hemnes AR, Robbins IM. Sildenafil monotherapy in portopulmonary hypertension can facilitate liver transplantation. Liver Transpl. 2009; 15:15-9.
282. Melgosa MT, Ricci GL, Garcia-Pagan JC, et al. Acute and long-term effects of inhaled iloprost in portopulmonary hypertension. Liver Transpl. 2010;16:348-56.
283. Keeffe EB. Liver transplantation at the millennium: past, present, and future. Clin Liver Dis. 2000;4:241-55. (Pubitemid 33041496)
284. Carey WD, Dumot JA, Pimentel RR, et al. The prevalence of coronary artery disease in liver transplant candidates over age 50. Transplantation. 1995;59:859-64.
285. Morris JJ, Hellman CL, Gawey BJ, et al. Case 3-1995: three patients requiring both coronary artery bypass surgery and orthotopic liver transplantation. J Cardiothorac Vasc Anesth. 1995;9:322-32.
286. Plotkin JS, Benitez RM, Kuo PC, et al. Dobutamine stress echocardiography for preoperative cardiac risk stratification in patients undergoing orthotopic liver transplantation. Liver Transpl Surg. 1998; 4:253-7. (Pubitemid 28323742)
287. Donovan CL, Marcovitz PA, Punch JD, et al. Two-dimensional and dobutamine stress echocardiography in the preoperative assessment of patients with end-stage liver disease prior to orthotopic liver transplantation. Transplantation. 1996;61:1180-8. (Pubitemid 26134767)
288. Tiukinhoy-Laing SD, Rossi JS, Bayram M, et al. Cardiac hemodynamic and coronary angiographic characteristics of patients being evaluated for liver transplantation. Am J Cardiol. 2006;98:178-81. (Pubitemid 43975507)
289. Plotkin JS, Scott VL, Pinna A, et al. Morbidity and mortality in patients with coronary artery disease undergoing orthotopic liver transplantation. Liver Transpl Surg. 1996;2:426-30. (Pubitemid 26386861)
290. Davidson CJ, Gheorghiade M, Flaherty JD, et al. Predictive value of stress myocardial perfusion imaging in liver transplant candidates. Am J Cardiol. 2002;89:359-60. (Pubitemid 34113805)
291. Williams K, Lewis JF, Davis G, Geiser EA. Dobutamine stress echocardiography in patients undergoing liver transplantation evaluation. Transplantation. 2000;69:2354-6. (Pubitemid 30409002)
292. Bradley SM, Soine LA, Caldwell JH, Goldberg SL. Screening stress myocardial perfusion imaging and eligibility for liver transplantation. Am J Cardiol. 2010;105:1010-3.
293. McAvoy NC, Kochar N, McKillop G, et al. Prevalence of coronary artery calcification in patients undergoing assessment for orthotopic liver transplantation. Liver Transpl. 2008;14:1725-31.
294. Budoff MJ, Achenbach S, Blumenthal RS, et al. Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology. Circulation. 2006;114:1761-91. (Pubitemid 44607126)
295. Sharma M, Yong C, Majure D, et al. Safety of cardiac catheterization in patients with end-stage liver disease awaiting liver transplantation. Am J Cardiol. 2009;103:742-6.
296. Bizouarn P, Ausseur A, Desseigne P, et al. Early and late outcome after elective cardiac surgery in patients with cirrhosis. Ann Thorac Surg. 1999;67:1334-8. (Pubitemid 29320228)
297. Klemperer JD, Ko W, Krieger KH, et al. Cardiac operations in patients with cirrhosis. Ann Thorac Surg. 1998;65:85-7. (Pubitemid 28105875)
298. Filsoufi F, Salzberg SP, Rahmanian PB, et al. Early and late outcome of cardiac surgery in patients with liver cirrhosis. Liver Transpl. 2007;13: 990-5. (Pubitemid 47163191)
299. Axelrod D, Koffron A, Dewolf A, et al. Safety and efficacy of combined orthotopic liver transplantation and coronary artery bypass grafting. Liver Transpl. 2004;10:1386-90. (Pubitemid 39530054)
300. Prabhakar G, Testa G, Abbasoglu O, et al. The safety of cardiac operations in the liver transplant recipient. Ann Thorac Surg. 1998;65:1060-4.
301. Garcia-Tsao G, Sanyal AJ, Grace ND, et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology. 2007;46:922-38. (Pubitemid 47436138)
302. Safadi A, Homsi M, Maskoun W, et al. Perioperative risk predictors of cardiac outcomes in patients undergoing liver transplantation surgery. Circulation. 2009;120:1189-94.
303. Allocca M, Crosignani A, Gritti A, et al. Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis. Gut. 2006;55:1795-800. (Pubitemid 44893581)